Funds managed by BlackRock added $40m to the $60m supplied for the drug development technology developer by investors including Novo, Evotec and Bristol Myers Squibb in May.
Month: March 2021
Lava Therapeutics flows toward public markets
Biox Biosciences, Novo, Sanofi and Merck & Co are all in line to exit the immuno-oncology therapy developer, which has filed for a $100m initial public offering.
Uplight upgrades to unicorn valuation
The utility engagement software provider secured the funding in a round co-led by Schneider Electric and AES Corporation at a $1.5bn valuation.
Corporates help Infcurion find $22m
Ceres, Dai Nippon Printing, Japan Post Investment, Money Forward, TIS and Toppan all backed the business development, incubation and investment company’s latest round.
Yugabyte records $48m round
The database platform developer will embark on international expansion with funding raised from investors including Dell Technologies Capital and Wipro Ventures.
Asuragen awaits results of $320m Bio-Techne acquisition
Merck & Co is set to exit the genomic services and cancer diagnostics provider in an acquisition by Bio-Techne potentially sized at $320m.
TaxBit takes $100m in series A round
PayPal Ventures and Coinbase Ventures are among the new investors in TaxBit, the creator of a cryptocurrency tax automation software platform.
Anghami tunes into $220m reverse merger
Du, MBC and Mobily are set to exit the music streaming platform operator as it agrees to list through a reverse takeover.
MoneyLion devours WTI in acquisition deal
The financial planning technology developer has been bought by MoneyLion just over a year after raising money from NFP Global.
Telus pops into PocketPills’ series B
Telus’ corporate venturing unit has led a $23.7m round for the Canadian online pharmacy as it seeks to take its coverage nationwide.
Sage muses on Countingup’s series A round
Sage participated in a $12.6m round for the business banking and accounting software provider that took its total funding above $21m.
Geneos gees itself up with $12m
Inovio Pharmaceuticals spinoff Geneos Therapeutics will put the proceeds from the series A1 round towards advancing its liver cancer vaccine candidate.
Emerging Leaders Q&A – Nicolas Autret, Samsung Catalyst Fund
Q&A with Nicolas Autret, investment director, Samsung Catalyst Fund
Arise cleans up with $12m Aera Group investment
Arise Industrial Services paid $12m for a 35% share of the carbon emissions certificate provider, valuing it at $34.5m.